Giant Cell Arteritis Treatment Guidelines

Introduction to Treatment

The typical duration of steroid therapy for Giant Cell Arteritis (GCA) is approximately 2 years or more before glucocorticoids can be completely discontinued, with a gradual tapering schedule targeting 15-20 mg/day within 2-3 months and ≤5 mg/day after 1 year, as recommended by the American College of Rheumatology 1
The American Heart Association and American College of Rheumatology recommend starting high-dose glucocorticoids, such as intravenous methylprednisolone 250-1000 mg/day for 3 days or oral prednisone 40-60 mg/day, for the initial treatment of inflammatory conditions like GCA 2, 3, 4

For patients with visual symptoms, consider starting at 60 mg/day of oral prednisone, as suggested by the American College of Rheumatology 1
Reduce to 15-20 mg/day within 2-3 months, and further taper to ≤5 mg/day after 1 year, according to the American College of Rheumatology 1
Inflammatory markers (ESR, CRP) should be monitored regularly, and glucocorticoids should be tapered gradually: aim for 15-20 mg/day within 2-3 months, and ≤5 mg/day after 1 year 4, 1, 3

Avoid rapid tapering as it significantly increases relapse risk, as warned by the American College of Rheumatology 1
Relapses are common during glucocorticoid tapering, with rates of 34-75% reported in observational studies, according to the American College of Rheumatology 1
For relapse, reinstitute or increase glucocorticoid dose (typically 5-15 mg/day above the last effective dose), as recommended by the American College of Rheumatology 1
Delaying glucocorticoid therapy when visual symptoms are present is the strongest risk factor for permanent blindness 1
For GCA recurrence, the initial dose of prednisone should be 40-60 mg/day, with the decision between 40 mg versus 60 mg based on severity of symptoms, previous response to treatment, presence of visual symptoms, and risk of glucocorticoid-related adverse events 1

Tocilizumab is recommended as first-line adjunctive therapy in selected patients, such as those with refractory or relapsing disease, by the American College of Rheumatology 1
Methotrexate may be used as an alternative adjunctive therapy, as suggested by the American College of Rheumatology 1
Methotrexate and tocilizumab may be used as alternative glucocorticoid-sparing agents or adjunctive therapy, especially in high-risk patients or those with refractory cases 1, 4, 5

Temporal artery biopsy (TAB) is the definitive diagnostic test for GCA, and should be performed within 2 weeks of starting steroids, with a segment greater than 1 cm in length 5
High-risk features of GCA include jaw claudication, temporal artery tenderness, and elevated erythrocyte sedimentation rate (ESR), with respective positive likelihood ratios of 4.90, 3.14, and 2.40 6
Noninvasive vascular imaging (CT angiography, MR angiography, or ultrasound) should be ordered to evaluate large vessel involvement 5

For patients with severe GCA with worsening limb/organ ischemia, immunosuppressive therapy should be escalated before considering surgical intervention 4
Immediate surgical intervention may be warranted for aortic aneurysms at high risk for rupture or impending tissue/organ infarction 4
For patients requiring vascular surgical intervention, high-dose glucocorticoids should be used during the periprocedural period if active disease is present 4
Aspirin should be considered for patients with critical involvement of vertebral or carotid arteries 4, 5

Regular clinical assessment for disease activity and treatment-related adverse effects is recommended 3, 4
Avoid alternate-day therapy as it increases relapse risk, and inadequate initial dosing may lead to increased risk of ischemic complications 3
Tapering glucocorticoids too rapidly can lead to disease relapse 3, 4